News About: Pharm. Industry
Government to Curb Prescription of High-Priced Medications
In an effort to curb the prescription of high-priced medications issued by hospitals and medical clinics, the Health Insurance Review Agency (HIRA) announced that individual healthcare providers could now obtain the l...
Domestic Firms Develop Silkworm Chrysalis Oil in Powder Form
Kolmar Korea and KunWha Pharmaceutical have successfully developed a novel functional ingredient from silkworm chrysalis, with potential commercialization opportunities as applied to cosmetic, nutraceutical and pharma...
Eisai Korea Obtains Sales and Marketing Rights for Excegran
Eisai Korea and Dong-A Pharmaceutical recently completed an agreement to transfer the domestic sales and marketing rights for anticonvulsant drug Excegran (active ingredient: zonisamide) from Dong-A to Eisai Korea, ef...
MSD Korea Receives Highest Quality Assessment Rating
MSD Korea recently received an award of recognition by Kyungin Regional Korea Food and Drug Administration (RKFDA) for the outstanding quality control and production management practices.
The recognition gave MSD K...
Active Marketing and Promotion by OTC Makers in Anticipation of Asian Dust
The domestic pharmaceutical firms are reported to actively engage in their marketing and promotion activities in anticipation of Asian Dust, known as Hwangsa in Korean, expected during the spring season of this year.
...
Samjin Launches U-GeneTest for Convenient DNA Testing
Samjin Pharmaceutical recently made an announcement to introduce a gene testing kit known as Samjin U-GeneTest, under an agreement for genetic business alliance with GeneBank, a domestic biotechnology venture firm.
...
Yungjin Plans to Attain Large-Scale Production Capability for Coenzyme Q10
In an effort to meet the surging demand for Coenzyme Q10 (CoQ10) in the global marketplace, Yungjin Pharmaceutical has announced of its plan to build a dedicated production plant with an annual output of CoQ10 up to 5...
Bukwang Withdraws Market Approval Request for Clevudine
Bukwang Pharmaceutical announced on March 7th that it has made an autonomous withdrawal of its application submitted for a domestic market approval of anti-hepatitis B agent clevudine to the Korea Food and Drug Admini...
Nexgen's EGFstable Registered to U.S. CTFA
Nexgen Biotechnologies Inc., a domestic venture firm specialized in second generation plant biotechnology, announced that it has made a successful registration of its EGFstable(TM), a novel hEGF (human Epidermal Growt...
Daewoong Chemical Takes Over Manufacturing Plant with Finished Product Capability
Daewoong Chemical announced last week of its pharmaceutical business extension into the finished product category, by assuming an ownership of Lilly Korea's manufacturing plant with injection, capsule and dry syrup pr...
